These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25208855)

  • 1. Assessment of retinal alterations after intravitreal ocriplasmin with spectral-domain optical coherence tomography.
    Itoh Y; Kaiser PK; Singh RP; Srivastava SK; Ehlers JP
    Ophthalmology; 2014 Dec; 121(12):2506-2507.e2. PubMed ID: 25208855
    [No Abstract]   [Full Text] [Related]  

  • 2. Early panretinal abnormalities on fundus autofluorescence and spectral domain optical coherence tomography after intravitreal ocriplasmin.
    Barteselli G; Carini E; Invernizzi A; Ratiglia R; Viola F
    Acta Ophthalmol; 2016 Mar; 94(2):e160-2. PubMed ID: 26010219
    [No Abstract]   [Full Text] [Related]  

  • 3. Understanding the adverse effects of ocriplasmin - reply.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2015 Feb; 133(2):229-30. PubMed ID: 25375214
    [No Abstract]   [Full Text] [Related]  

  • 4. Vision loss after intravitreal ocriplasmin: correlation of spectral-domain optical coherence tomography and electroretinography.
    Tibbetts MD; Reichel E; Witkin AJ
    JAMA Ophthalmol; 2014 Apr; 132(4):487-90. PubMed ID: 24577286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the adverse effects of ocriplasmin.
    Beebe DC
    JAMA Ophthalmol; 2015 Feb; 133(2):229. PubMed ID: 25376025
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding the adverse effects of ocriplasmin - reply.
    Johnson MW; Fahim AT
    JAMA Ophthalmol; 2015 Feb; 133(2):230. PubMed ID: 25375273
    [No Abstract]   [Full Text] [Related]  

  • 7. [Unclear retinopathy after intravitreal injection of ocriplasmin].
    Abraham S; Wand K; Stumpfe S; Feucht N; Lohmann CP; Maier M
    Ophthalmologe; 2016 Feb; 113(2):156-9. PubMed ID: 26205745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe acute vision loss, dyschromatopsia, and changes in the ellipsoid zone on sd-oct associated with intravitreal ocriplasmin injection.
    Quezada Ruiz C; Pieramici DJ; Nasir M; Rabena M; Avery RL
    Retin Cases Brief Rep; 2015; 9(2):145-8. PubMed ID: 25462129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute panretinal structural and functional abnormalities after intravitreous ocriplasmin injection.
    Fahim AT; Khan NW; Johnson MW
    JAMA Ophthalmol; 2014 Apr; 132(4):484-6. PubMed ID: 24577241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PERSISTENT RETINAL CHANGES AFTER INTRAVITREAL OCRIPLASMIN.
    Margo JA; Schocket LS; Klima K; Johnson MA
    Retin Cases Brief Rep; 2016; 10(1):48-51. PubMed ID: 26682796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocriplasmin for symptomatic vitreomacular adhesion.
    Neffendorf JE; Kirthi V; Pringle E; Jackson TL
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed transient corneal edema after intravitreal injection of ocriplasmin.
    Zhang TY; Vachon-Joannette É; Proulx S; Légaré ME; Bourgault S
    Can J Ophthalmol; 2018 Apr; 53(2):e77-e79. PubMed ID: 29631850
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute vision loss after ocriplasmin use.
    Reiss B; Smithen L; Mansour S
    Retin Cases Brief Rep; 2015; 9(2):168-9. PubMed ID: 25741635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible vision loss and outer retinal abnormalities after intravitreal ocriplasmin injection.
    Thanos A; Hernandez-Siman J; Marra KV; Arroyo JG
    Retin Cases Brief Rep; 2014; 8(4):330-2. PubMed ID: 25372540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WIDESPREAD MACULAR NEUROSENSORY DETACHMENT AFTER OCRIPLASMIN INTRAVITREAL INJECTION.
    Neffendorf JE; Lim LT; Gout II; El-Amir A
    Retin Cases Brief Rep; 2016; 10(4):354-6. PubMed ID: 26674272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou?
    Kim JE
    JAMA Ophthalmol; 2014 Apr; 132(4):379-80. PubMed ID: 24577332
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment outcomes and spectral-domain optical coherence tomography findings of eyes with symptomatic vitreomacular adhesion treated with intravitreal ocriplasmin.
    Warrow DJ; Lai MM; Patel A; Raevis J; Berinstein DM
    Am J Ophthalmol; 2015 Jan; 159(1):20-30.e1. PubMed ID: 25220823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications of intravitreal ocriplasmin for vitreomacular traction and macular hole: a prospective spectral-domain optical coherence tomography study.
    Chatziralli IP; Theodossiadis GP; Parikakis E; Datseris I; Theodossiadis P
    Cutan Ocul Toxicol; 2016 Dec; 35(4):263-9. PubMed ID: 26555379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute loss of vision after an intravitreal injection ocriplasmin: a functional evolutionary study for 1-year follow-up.
    Gómez-Ulla F; Bande MF; Abraldes M
    Doc Ophthalmol; 2015 Dec; 131(3):231-5. PubMed ID: 26542118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
    Luttrull JK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.